Home › Compare › SPONF vs ABBV
SPONF yields 20000000.00% · ABBV yields 3.06%● Live data
📍 SPONF pulled ahead of the other in Year 1
Combined, SPONF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPONF + ABBV for your $10,000?
SponsorsOne Inc., a technology company, develops and operates a cloud-based social sponsorship platform in the United States and Canada. The company develops SponsorsCloud, a platform for connecting and facilitating one-to-one engagement between corporations and users within social networks. It also operates SponsorCoin, a platform that integrates with social networks and enables the delivery of social media marketing campaigns into the social channels, and facilitates transactions through its proprietary platform, which supports the exchange of goods and services between brands and influencers using its digital currency SponsorCoin. In addition, the company manufactures and develops spirits and ready-to-drink spirits, gin, and vodka under the Meet Doc Wylder's, Smithville, Four Corners, and Riverview brands; and hemp smokes under the Primero, Suede, and Reign brands. The company is headquartered in Uxbridge, Canada. SponsorsOne Inc. is a subsidiary of The Gummy Project Inc.
Full SPONF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.